An informative and comprehensive analysis of existing research studies evaluating the merits of early vs. deferred commencement of hormone therapy in men with advanced prostate cancer was recently published. The analysis (Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database of Systematic [...]
Today, Cougar Biotechnology, Inc. (NASDAQ:CGRB) unveiled the results from its ongoing Phase II clinical trial drug CB7630 (abiraterone acetate). The data was presented at the Prostate Cancer Foundation Scientific Retreat in Lake Tahoe, Nevada. The clinical trial, which is centered at the M.D. Anderson Cancer Center in Texas and was designed to look at the [...]
As advanced prostate cancer progresses it becomes inevitable that we will develop bone metastases. The treatments available are designed to slow disease progression, to relieve pain and to avoid the complications that result from bones being weakened by the cancer. Weakened bones become very susceptible to fractures, with prostate cancer the most likely sight for [...]
The number of men with Hormone Refractory Prostate Cancer (HRCP) is ever increasing; some statisticians feel that it could eventually become the most common cancer in the male population. The clinical variability, the lack of consensus on patients' eligibility for starting a different treatment, and the response criteria seen in literature have made it difficult [...]
In today’s New York Times Gina Kolata wrote a very interesting article about the unreliability of MRIs for diagnostic purposes. She wrote from the perspective of orthopedic injuries, but since MRIs are main stays for us suffering with prostate cancer, there is an important message for us. Her story revolves around a running injury that [...]